Blastocyst transfer, combined with vitrification, can maximize the cumulative pregnancy rate per oocyte retrieval cycle.
| INTRODUC TI ON
Blastocyst transfer, combined with vitrification, can maximize the cumulative pregnancy rate per oocyte retrieval cycle. 1 In contrast to early-stage embryos, blastocysts represent more mature, naturally selected embryos with a higher potential for development and implantation after in vitro fertilization (IVF). 2 From the viewpoint of vitrified blastocyst transfer programs, assisted reproductive technology requires that blastocysts be completely vitrified to enhance the IVF success rate. 3, 4 However, Vanderzwalmen et al 5 found that the survival rate after vitrification/warming depended on the stage of blastocyst development, with expanded blastocysts exhibiting lower survival rate than morulae or early cavitating blastocysts. Expanded blastocysts are prone to forming ice crystals during vitrification due to large amounts of water-based fluid in the blastocele cavity. This may cause ultrastructural damage and interfere with the exchange of cryoprotectants presented in vitrification media. Although cryoprotectant agents (CPAs) usually cause the blastocyst to collapse during vitrification, 6 it varies considerably depending on the intensity of shrinkage during the previtrification phase.
Some investigators found that artificial shrinkage (AS) of the blastocyst was effective for avoiding intracellular ice formation during vitrification. AS was aimed at dehydrating and collapsing the blastocele cavity before blastocyst vitrification. It can be performed in a variety of ways, including laser pulse shooting, 7 repeated pipetting of the blastocyst, 8 exposure to hyperosmotic sucrose solution, 9 microneedle puncture, 5, 10 and mechanical microsuction (MS) of the blastocele contents. 11 Several authors have reported that previtrification AS for the blastocyst improved the survival rate and clinical outcomes of blastocyst cryopreservation programs. 7, 10, 12 Blastocysts were observed to be completely collapsed when MS was applied.
However, research has not been frequently published that included information about live birth of a healthy infant after MS treatment.
This study retrospectively evaluated the clinical and neonatal outcomes of blastocelic MS
| MATERIAL S AND ME THODS

| Experimental data
This was a retrospective, observational study based on data collected between March 2014 and August 2016. Data were collected from 211 patients whose causes of infertility were male factor, female factor (such as ovulatory disorders and endometriosis), and/or unexplained infertility. A total of 317 blastocysts were warmed, and each was transferred to the uterus of a patient. Participation of patients in this study was obtained through an opt-out methodology. The Kurashiki Medical Center and Ethics Committee approved the project.
| Blastocyst preparations
In the oocyte retrieval cycle, ovarian stimulation was achieved using standard gonadotropin-releasing hormone agonist/follicle-stimulating hormone (FSH) protocols or an antagonist/FSH protocol. Vaginal ultrasound-guided follicle puncture was conducted at 36 hours after the human chorionic gonadotropin (Mochida) injection. The retrieved oocytes were inseminated by conventional IVF or intracytoplasmic sperm injection (ICSI) in accordance with a previously reported method. 13 The oocytes with two pronuclei and a second polar body were defined as normally fertilized at 17-19 hours after insemination. They were cultured for five days in medium (global ® ;
Life Global) supplemented with recombinant human albumin (G-MM;
Vitrolife) at 37°C in 6% CO 2 , 5% O 2, and 89% N 2 . On day 5, the blastocysts were evaluated for expansion. A morphological grade was given according to the Istanbul Consensus criteria. 14 Only blastocysts with diameter of 170 µm or wider were included in this study.
| Artificial shrinkage treatment
Artificial shrinkage treatment was performed following the method described in Chen et al. 11 The blastocyst was held with a 
| Blastocyst vitrification and warming
The collapsed blastocysts were vitrified and warmed (Kitazato 
| Transfer of postwarmed blastocysts
Blastocyst survival was defined as partially intact after warming and re-expansion after culture in vitro before transfer. Each surviving blastocyst was transferred to a patient's uterus. Common modalities for blastocyst transfer were natural cycles or hormonal replacement cycles for endometrial preparation. Blastocyst transfer was performed under ultrasound guidance using embryo transfer catheter.
| Follow-up and evaluation index
To confirm the establishment of a clinical pregnancy, an ultrasound check was performed to visualize a gestational sac and fetal heartbeat. The loss of fetus with a gestational age of <20 weeks was considered a spontaneous abortion. A live birth rate was defined as live birth delivery cycles divided by transfer cycles. Preterm birth was defined as <37 gestational weeks. Birthweight <2500 g was defined as low birthweight. The duration of pregnancy, mode of delivery, and weight and sex of the child were recorded as neonatal outcomes.
Cumulative implantation rate and cumulative live birth rate were the proportion of women that had at least one implantation and live birth, whether from the first transfer attempt or subsequent transfers of vitrified supernumerary blastocysts after the oocyte retrieval. Once a woman obtained a pregnancy from vitrified embryo transfer, she did not contribute any more to the cumulative rate.
| Statistical analysis
Analyses were done using the Statcel 2 program (OMS Publishing).
Continuous variables were represented as mean ± SD and investigated to determine whether they were normally distributed. All continuous variables were not normally distributed, and the MannWhitney U test was used to compare the MS and non-MS groups (NMS). Categorical variables were described as frequency and percentage, with between-group difference tested by the chi-squared test and Fisher's exact test when the expected frequencies were <5.
Odds ratio (OR) with 95% confidence interval was analyzed using an online calculator. P < 0.05 was considered statistically significant.
| RE SULTS
The patient characteristics are summarized in Table 2 .
The neonatal outcomes of 62 children born after transfer are shown in Table 3 . Thirty-two babies were born in the MS group, and 30 babies were born in the NMS group. There were no differences between the MS and NMS groups with respect to the average gestational weeks (37.8 ± 3.4 weeks vs 38.2 ± 1.5 weeks), preterm birth rate (9.4% vs 13.3%), mean birthweight (2810.3 ± 707.9 g vs 3076.8 ± 409.1 g), and low birthweight rate (12.5% vs 3.3%).
The cesarean section (37.5% vs 43.3%), proportion of male babies (37.5% vs 50.0%), and congenital abnormality rates (3.1% vs 0%) also had no differences. One baby with cleft lip was born in the MS group.
| D ISCUSS I ON
The MS blastocyst survival was significantly higher than the NMS blastocyst survival. Furthermore, MS had little effect on further embryo development after warming.
There is a fundamental problem that AS for blastocysts prior to vitrification is successful in some laboratories but not in others. It is challenging to explain the reason for this discrepancy, because many factors may affect the survival rate of human blastocyst vitrification, such as the method of AS, protocols of vitrification, types of carrier used for vitrification, previtrification handling of blastocysts, quality and size of blastocysts, and criteria for survival of warmed blastocysts. In our experience, the survival rate declines in completely expanded blastocysts after warming without AS prior to vitrification.
This leads to performing AS prior to vitrification when blastocyst size is large. We tried various AS methods with expanded blastocysts, including repeated pipetting of the blastocyst, 8 exposure to hyperosmotic sucrose solution, 9 and laser pulse shooting. 7 Nevertheless, we could not reproduce the satisfactory results described in those papers. We then tried the MS method, and a high survival rate was obtained after vitrification of large-sized blastocysts, as demonstrated in this study. These results are similar to previous reports. 11, 16, 17 Among various methods of AS, laser puncturing of blastocysts before vitrification is the most popular. We tried laser pulse shrinkage of expanded blastocysts following Mukaida's method. 7 One to three laser pulses (0. 
Note: Significant at P < 0.05. Abbreviation: CI, confidence interval; MS, microsuction; NMS, non-microsuction. a Defined as a gestational sac identified with ultrasound. As a result, MS was used as a primary AS method in our laboratory and used in this study design. We analyzed small numbers of blastocysts in unpublished data, and it was difficult to conclude whether laser or MS was better. In our experience, poor-quality blastocysts often degenerated after laser puncturing, although it should be interpreted with caution due to the small sample size. Mukaida et al 7 to achieve high survival rates of embryos after vitrification, but they did not mention whether the equilibration period could be shortened. In our laboratory, four embryos are vitrified in 15 minutes. The embryos are exposed to equilibration medium at least 5 minutes, and then, each is sequentially vitrified every 2 minutes. In other words, we start vitrifying the first embryo at 5 minutes after exposure in equilibration medium and the final embryo at 11 minutes or later. It may be enough for blastocysts to expose in equilibration medium at least 5 minutes before vitrification, and initial equilibration periods up to 15 minutes may have little effect on human embryos and further development.
TA B L E 2 Clinical outcomes with MS and NMS groups
TA B L E 3 Neonatal outcomes with MS and NMS groups
In conclusion, this study shows that the MS method reduces blastocelic fluid prior to vitrification and may enhance the survival and implantation rates after warming. The MS method group also tends to have better clinical outcomes than nontreatment group.
Because total available numbers of surviving MS blastocyst will be increasing, the cumulative clinical outcomes will be expected to be high in further large-scale studies. Further prospective randomized studies will be needed to confirm the findings of this study. 
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